Search

Displaying results 401 - 410 of 450 in total
  1. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

  2. Drug

    Aloe vera leaf

    go.drugbank.com/drugs/DB13906
    ApprovedInvestigational

    Aloe describes a genus including over 500 species of flowering succulent plants that grow in the Southern peninsula and various islands. Aloe vera, or Aloe barbadensis miller, is the most common species of Aloe that is cultivated for agr...

  3. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601]

  4. Drug

    Budesonide

    go.drugbank.com/drugs/DB01222
    ApprovedInvestigational

    Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was granted FDA approval o...

  5. Drug

    Carfentanil

    go.drugbank.com/drugs/DB01535
    IllicitInvestigationalVet approved

    Carfentanil or carfentanyl (Wildnil) is an analogue of the popular synthetic opioid analgesic fentanyl, and is one of the most potent opioids known (also the most potent opioid used commercially). Carfentanil was first synthesized in 197...

  6. Drug

    3-Methylfentanyl

    go.drugbank.com/drugs/DB01571
    ExperimentalIllicit

    3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000 times more potent than morphine in ...

  7. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427]. … Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia.

  8. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    In a global, prospective, controlled, multi-center Phase 2/3 open-label clinical trial, all patients responded to susoctocog alfa treatment within 24 hours [L1129].

  9. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [L49469] This approval was based on positive results demonstrated in the open-label, single-arm Phase 3 BENEGENE-2 study, where the annualized bleeding rate (ABR) was observed to be 1.3 for the 12 months

  10. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.